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Abstract
Background: New evidence suggests that obesity is delete-
rious for bone health, and obesity treatments could poten-
tially exacerbate this.
Materials and methods: This narrative review, largely 
based on recent systematic reviews and meta-analyses, 
synthesizes the effects on bone of bariatric surgery, weight 
loss pharmaceuticals and dietary restriction.
Results and conclusions: All three obesity treatments 
result in statistically significant reductions in hip bone 
mineral density (BMD) and increases in bone turnover 
relative to pre-treatment values, with the reductions in hip 
BMD being strongest for bariatric surgery, notably Roux-en 
Y gastric bypass (RYGB, 8%–11% of pre-surgical values) 
and weakest for dietary restriction (1%–1.5% of pre-treat-
ment values). Weight loss pharmaceuticals (orlistat or 
the glucagon-like peptide-1 receptor agonist, liraglutide) 
induced no greater changes from pre-treatment values 
than control, despite greater weight loss. There is sug-
gestive evidence that liraglutide may increase bone min-
eral content (BMC) – but not BMD – and reduce fracture 
risk, but more research is required to clarify this. All three 
obesity treatments have variable effects on spine BMD, 
probably due to greater measurement error at this site in 
obesity, suggesting that future research in this field could 
focus on hip rather than spine BMD. Various mechanisms 
have been proposed for BMD loss with obesity treatments, 
notably reduced nutritional intake/absorption and insuf-
ficient exercise, and these are potential avenues for pro-
tection against bone loss. However, a pressing outstanding 
question is whether this BMD reduction contributes to 
increased fracture risk, as has been observed after RYGB, 
and whether any such increase in fracture risk outweighs 
the risks of staying obese (unlikely).
Keywords: bariatric surgery; diet reducing; glucagon-like 
peptide-1 receptor agonists; orlistat; weight loss.
Introduction
There are currently over 2 billion adults in the world with 
a body mass index (BMI) in the overweight or obese range 
[1]. This obesity epidemic imposes an enormous burden 
on individuals and societies by increasing the incidence 
and severity of health complications and diseases affect-
ing multiple aspects of the body and mind.
Bone is one of very few aspects of health that have 
been considered to not be adversely affected by obesity. 
In fact, obesity was even considered to provide protection 
against osteoporosis [an excessive loss of bone mineral 
density (BMD) that predisposes to fractures], due to the 
effect of weight-bearing to increase BMD [2]. However, this 
stand has been challenged recently, with observations that 
obesity is associated with deficiencies in nutrients impor-
tant to bone health such as calcium [3] and vitamin D [4, 5], 
in addition to perturbations in bone metabolism [5], possi-
ble bone loss [6] and higher fracture risk [7]. Indeed, while 
low BMI (< 18.5 kg/m2) is clearly associated with low BMD 
and a higher risk of fracture, new research shows that the 
relationship between higher BMIs and fracture risk is non-
linear [8]. Now, obesity is no longer considered to be protec-
tive against osteoporosis and fracture [9–12]. Obesity per se 
is increasingly recognized as a state of heightened fracture 
risk in both men and women [7, 8]. For instance, a study 
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involving over 60,000 women from 10 countries revealed 
an association between BMI ≥ 30 kg/m2 and increased risk 
of ankle and upper leg fractures (with reduced risk of wrist 
fractures) [7], and a similar correlation was also found in 
men, albeit only after correction for the increased BMD gen-
erally associated with obesity [8], and not without contro-
versy [13]. Interestingly, these fracture sites [7] differ from 
the fracture sites most commonly seen in osteoporosis, 
which are the wrist, upper arm, rib, hip and spine [7]. A 
number of possible contributors to compromised skeletal 
health in obesity have been proposed, including but not 
limited to reduced vitamin D bioavailability [9, 14] and an 
inflammatory state that increases bone breakdown [15]. 
Moreover, individuals with obesity have a heightened risk 
of mobility impairment [16] and falls [17, 18], due to factors 
such as poor compensatory stepping responses and pos-
tural instability [17] as well as intramuscular fat infiltration 
which reduces muscle strength [9, 19, 20]. While fat padding 
surrounding particular bones such as the pelvis and femur 
lessens the impact of falls [21], it is conceivable that falls 
in obese individuals might lead to a greater force on other 
bones due to the laws of physics. Indeed, falls in individu-
als with obesity are often more serious than in non-obese 
individuals, resulting in longer hospitalisations [22].
Not only does obesity impose functional risks for bone 
health, treatments for obesity have now been shown to 
impair the intake and absorption of nutrients important for 
bone health, to compromise bone metabolism, to reduce 
BMD and possibly also increase fracture risk. These effects 
of obesity treatments – specifically bariatric surgery, 
weight loss pharmaceuticals and dietary restriction – will 
be synthesized in the current narrative review, which is 
largely based on systematic reviews and meta-analyses 
that have been recently published in this area. By drawing 
together the effects of these three obesity treatments on 
bone into a single review, our intention is to crystalize gaps 
in knowledge that may not be apparent when reflecting on 
individual treatment modalities, as well as considering the 
relative risks versus benefits of obesity treatments overall.
Overview of bone physiology
An understanding of general principles of bone physiol-
ogy is important for appreciation of this review.
Structure of bone
There are two major types of bone tissue; cortical bone 
(also called compact bone), which is dense and solid, and 
makes up the characteristic outer hard layer of bones and 
forms the majority of the long bone structure, and trabec-
ular bone (also called cancellous bone, or spongy bone), 
which is softer and ‘spongier’ in appearance, as the name 
implies, and can be found in the middle of bones such as 
vertebrae and the long bones [23].
Both cortical and trabecular bone have various types 
of bone cells interspersed throughout their structures. 
These include osteoprogenitor cells, osteoblasts, osteo-
cytes and osteoclasts. Osteoprogenitor cells, the precur-
sors to osteoblasts, are found on both the interior and 
exterior surfaces of bone, and also in association with 
bone microvasculature [24]. Osteoblasts are responsible 
for bone formation, as they function to secrete and calcify 
the bone matrix. Once osteoblasts are enveloped in the 
mineralized bone matrix, they stop secretion of matrix 
and are referred to as osteocytes. Osteocytes are the most 
abundant type of bone cell, and are involved in regulat-
ing the balance between bone secretion by osteoblasts 
and bone resorption by osteoclasts. Osteoclasts arise 
when mononuclear haemopoietic cells fuse to form larger, 
multi nucleated cells. These cells are located primarily on 
bone surfaces, where resorption takes place [24, 25].
Bone turnover
Even in the absence of significant skeletal injuries or disor-
ders, bone is continuously involved in a process of remod-
eling (bone formation and resorption), which contributes 
to calcium homeostasis and repairs micro fractures [26]. 
The volume of bone that is both formed and resorbed 
during this continuous process at a given time is referred 
to as bone turnover [27]. Bone formation and resorption 
are coupled, as bone resorption by osteoclasts is closely 
followed by osteoblast formation and bone secretion [28]. 
Therefore, in instances of bone catabolic states, there is an 
increase in both bone formation and resorption [29].
Analysis of bone
Dual energy X-ray absorptiometry (DXA)
DXA is the standard reference method for measuring BMD, 
a factor used for the diagnosis of osteoporosis [30]. BMD 
is dependent on the net balance between bone forma-
tion and resorption, however, these changes cannot be 
detected by DXA scans until substantial bone turnover 
has taken place, which can take between 6 and 12 months 
depending on the stimulus [10, 31]. Moreover, the precision 
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of DXA scans has been shown to decline with increasing 
BMI [32], as well as when measuring BMD in people who 
are not weight-stable (i.e. undergoing dynamic changes in 
body weight) [33]. These imprecisions are due to several 
reasons, notably difficulties in positioning patients/par-
ticipants on the scanning bed, fractures in the vertebrae, 
which heighten apparent spinal BMD, and artifact errors 
caused by changing amounts of fat tissue surrounding 
bones [10, 12, 34]. Indeed, the presence of fat around bone 
can result in unpredictable errors in DXA bone measure-
ments of up to 20%, as determined by experiments where 
phantom bone models or lean participants were wrapped 
with plastic bags containing semi-solid fat [33, 35]. This 
error may be due in part to artifact effects of soft tissues, 
as well as to the effect of fat mass and changes in fat mass 
to alter the distance between the X-ray source and the 
bone site under investigation [33]. Another technical limi-
tation of DXA is that its dual energy X-ray sources can only 
measure two tissue types at any one time (e.g. bone and 
soft tissue). Thus, being a two-compartment model for 
the determination of body composition, DXA calculations 
assume certain ratios of fat to lean tissues to determine 
the density of fat, lean and bone tissues. However, these 
assumed ratios may be violated in obesity and with weight 
changes (e.g. after weight loss) [33]. Despite these limita-
tions, DXA is still used and recommended as the principle 
method for assessing bone mass, even in obesity [10, 31, 
36]. Nevertheless, it has been suggested that when con-
ducting and interpreting data from studies that present 
potential DXA measurement errors (as in the case of 
obesity treatments), it is crucial that the DXA scanner be 
calibrated correctly [36], and that other modes of assess-
ing bone mass are used for confirmation.
Computed tomography (CT)
Some of the limitations of using DXA to track bone in 
people with obesity in response to weight loss may be 
overcome by the use of computed tomography (CT), which 
has greater sensitivity for detecting changes in bone 
density [37] and – unlike DXA – is able to provide insights 
into micro architectural changes in cortical and trabecular 
bone [23]. However, this technique is not widely available 
for bone analyses in clinical or research settings, and – 
when it is available – peripheral sites such as the forearm 
or foreleg are more amenable to CT scanning than the tra-
ditional sites of bone analysis for the assessment of frac-
ture risk (hip and spine) [38]. A further deterrent to the use 
of CT in serial analyses of human bone is the fact that with 
current technology, radiation exposure from a CT scan 
is approximately 10-fold greater than that of a DXA scan 
[39]. As such, there is limited research that has assessed 
changes in bone using CT during obesity treatments.
Markers of bone turnover
Due to the above limitations of DXA scanning, especially 
in individuals with obesity and in those undergoing 
weight flux, as well as the above limitations of CT scan-
ning, biomarkers (or markers) of bone turnover can and 
should be used as an adjunct to DXA scans when assess-
ing bone health. In our recent systematic review and 
meta-analysis [34], we noted that markers of bone turn-
over that have been commonly used include N-terminal 
propeptide of type I procollagen (P1NP) and osteocalcin 
for bone formation, and C-terminal telopeptide of type I 
collagen (CTX) and N-terminal telopeptide of type I col-
lagen (NTX) for bone resorption [40–42]. P1NP and CTX 
have recently been recommended as the standardized 
reference markers for bone formation and resporption, 
respectively [40–42]. Other markers include serum bone-
specific alkaline phosphatase (BAP) for bone formation, 
and the ratio of fasting concentrations of urinary hydroxy-
proline/creatinine (fU-OHpr/creat) and serum tartrate-
resistant acid phosphatase (TRAP5B) for bone resorption, 
but these are less commonly measured and will not be dis-
cussed in further detail here.
The marker of bone formation P1NP is produced by 
the enzymatic breakdown of type I procollagen, which 
is secreted by osteoblasts [23]. While P1NP could origi-
nate from other sources besides bone, these non-skeletal 
sources contribute minimally to circulatory fractions, as 
these tissues have a slower turnover rate than bone [43]. 
Osteocalcin, an osteoblast-derived cytokine, is another 
sensitive marker of osteoblast activity, and therefore bone 
formation [25]. Although it is not now considered a stand-
ard reference marker of bone formation, its widespread 
use in previous studies over many years has contributed 
to its ongoing use, as a means of comparison of bone turn-
over in new studies with that reported in previous studies. 
A recent study spurred potentially further interest in the 
measurement of serum osteocalcin levels as a marker 
of bone formation, by showing a significant association 
between serum osteocalcin concentrations with incident 
hip fracture risk in older men, whereas there was no sig-
nificant association between serum P1NP concentrations 
and hip fracture after adjusting for other relevant risk 
factors in this population [44]. A potential source of error 
with osteocalcin, however, is that due to the incorporation 
of osteocalcin into the bone matrix, it has been suggested 
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that osteocalcin fragments may be released even during 
bone resorption [45–47].
CTX and NTX are formed by osteocalasts from the 
degradation of type I collagen during bone resorption. 
One difficulty when assessing these telopeptides as bone 
resorption markers is their diurnal variability. Sample 
collection from serum or urine in a fasted state has been 
shown not only to reduce these variations, but also to 
increase analyte sensitivity [48].
Effect of obesity treatments on bone
A number of clinical trials have investigated BMD and 
bone turnover in response to obesity treatments, notably 
bariatric surgery, weight loss pharmaceuticals and dietary 
restriction. The mass of information available from these 
clinical trials has recently enabled systematic reviews and 
meta-analyses to be conducted. Looking at these three 
obesity treatments together, as opposed to separately as is 
usually the case, has revealed interesting commonalities 
that help to inform further research and clinical practice 
in the field. These findings are summarized in Table 1.
Effect of bariatric surgery on bone
Bariatric surgery is an increasingly prevalent treatment 
option for obesity with demonstrated short and long term 
efficacy for weight loss and in reducing obesity-associated 
co-morbities [49]. The three most commonly performed 
bariatric surgeries are Roux-en-Y gastric bypass (RYGB), 
laparoscopic adjustable gastric banding (gastric banding), 
and sleeve gastrectomy [50]. In RYGB, the stomach is 
stapled to create a small pouch, which reduces the amount 
of food that can be consumed. This small pouch is then 
directly attached to the small intestine, which effectively 
bypasses the rest of the stomach and the upper part of the 
small intestine, thus considerably reducing the surface 
area available for absorption of nutrients [50]. Patients 
undergoing RYGB typically lose 35% of their initial body-
weight, which corresponds to a loss of 62%–75% of excess 
body weight [51]. Gastric banding involves an adjustable 
band being placed around the stomach, thereby allow-
ing only small amounts of food to be consumed at a time. 
It typically results in a loss of between 20% and 30% of 
initial body weight [52], which is equivalent to a loss of 
41%–54% of excess body weight [49]. Sleeve gastrec-
tomy is a newer but increasingly common procedure in 
which over 80% of the stomach is removed, resulting in 
nutrients rapidly passing through the stomach and alter-
ing gut hormones and metabolism [50, 52]. It can produce 
body weight losses of between 20% and 30% of initial 
body weight, which is equivalent to a 45%–64% of excess 
body weight [10, 52].
Despite the successful weight loss outcomes of bari-
atric surgery for patients with obesity, detrimental effects 
on bone have been reported [10, 53]. BMD has been found 
to be significantly decreased post bariatric surgery, with 
differing results between surgery types [10, 54–56]. Most 
available information about the effects of bariatric surgery 
on bone comes from studies on RYGB. It appears to have 
a greater detrimental effect on bone than gastric banding 
or sleeve gastrectomy – not only in terms of reducing 
BMD, at least at the hip, but also in terms of increasing 
the risk of osteoporotic fractures [10, 50, 55–58]. Hip BMD 
has been shown to decrease by 8%–11% from pre-surgical 
values in the first 12 months after RYGB [10, 50, 56, 59, 60]. 
A systematic review and meta-analysis of 12 trials (three 
randomized controlled trials and nine quasi experimental 
trials) showed that reductions in hip BMD after RYGB or 
another less common bariatric procedure, biliopancreatic 
diversion, were significantly greater than the reductions 
induced by gastric banding or sleeve gastrectomy, when 
measured 12  months post surgery [56]. The change from 
pre-surgical values in hip BMD in the RYGB group (nine 
trials involving RYGB and one trial involving biliopancre-
atic diversion) was –0.12 g/cm2, and in the other surgical 
group (one trial involving gastric banding and two trials 
involving sleeve gastrectomy) it was –0.04 g/cm2 [56]. 
These findings for sleeve gastrectomy are in keeping with 
a trial of shorter duration in 29 women, which was not 
included in the above-mentioned systematic review and 
meta-analysis [61]. Indeed, at 6  months post sleeve gas-
trectomy, BMD losses relative to pre-surgery values were 
observed at the hip (–0.059 ± 0.030 g/cm2 or –5.2%) and 
femoral neck (–0.072 ± 0.046 g/cm2 or –7.0%), with a slight 
but significant decrease at the lumbar spine [61].
One disadvantage of studies that investigate pre- 
versus post-surgical BMD is that they do not control for 
changes in BMD that would have occurred over time in 
the absence of any intervention. Addressing this limita-
tion, a systematic review and meta-analysis published in 
2015 investigated 10 studies that compared BMD between 
a non-surgical control group (n = 261) with participants 
that had bariatric surgery (n = 241), with DXA scans 
being conducted at 10  months to 10  years post-surgery 
[55]. There were seven studies involving RYGB, one study 
involving a mixture of RYGB and another bariatric proce-
dure, namely vertical banded gastroplasty, one study on 
vertical banded gastroplasty alone, and one study with 
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an unspecified bariatric surgical type. This meta-analysis 
showed significantly lower BMD at the femoral neck in 
the surgical than in the non-surgical control group, but 
only by –0.005 g/cm2, with no difference between oper-
ated and non-operated groups in lumbar spine BMD [55]. 
This finding of reduced BMD at the hip but not the spine 
after bariatric surgery is in keeping with observations 
that although gastric banding has been shown to signifi-
cantly reduce hip BMD [56], it is associated with a small, 
but significant, increase relative to pre-surgical values 
in lumbar spine BMD at 12 [62] and 24 months [57] after 
surgery.
While the above-mentioned cross-sectional study 
investigated patients versus non-surgical controls at up 
to 10  years post surgery, few prospective studies have 
reported on BMD relative to pre-surgical values at time 
points > 12  months post bariatric surgery. However, one 
prospective study in 59 women who underwent RYGB 
found that femoral neck BMD decreased by a further 3% 
between 12 and 36  months post surgery, after an initial 
10% decline in the first 12 months post surgery [63]. These 
decreases in hip BMD were more marked in post-men-
opausal than in pre-menopausal women, albeit all hip 
BMD values at 36  months post-surgery remained higher 
than corresponding values in women of the same age 
from the general population [63], likely due to the effect 
of elevated BMI to increase BMD [64]. Conversely, another 
study found a decrease in total hip BMD of 9% between 
pre-surgical values and 12 months post RYGB or biliopan-
creatic diversion, but there were no further significant 
declines in total hip BMD between 12 and 24  months or 
24 and 36 months post surgery [65]. In keeping with this 
latter finding, subgroup analysis in the above-mentioned 
2015 meta-analysis that compared RYGB and other bariat-
ric surgery types with non-operated controls, showed that 
studies with a time point of ≥ 24 months post surgery dem-
onstrated no difference in femoral neck or lumbar spine 
BMD between operated and non-operated groups [55]. 
This could indicate that the effect of bariatric surgery to 
reduce BMD may be transient, but further work is required 
to clarify this possibility.
Lower BMD is linked to a greater risk of fracture, and a 
significant association between bariatric surgery and frac-
ture has been reported [66, 67]. In a 12-year cohort study 
involving 2064 patients who underwent any of 10 types 
of bariatric surgery between 2001 and 2009, compared 
to 5027 matched controls, those that underwent bariat-
ric surgery showed a non significant 1.41-fold increased 
fracture risk at 12–24  months post surgery compared to 
matched controls (95% confidence interval: 0.99–2.05) 
[66]. At the end of the 12-year study period, however, there 
was a significant 1.21-fold increased fracture risk (1.02–
1.42) in the operated compared to the non-operated group 
[66]. Interestingly, the increased fracture risk was only 
seen in sites that are not typically targets of osteoporo-
tic fractures, namely the clavicle/scapula/sternum and 
feet/toes – and not in the common osteoporotic fracture 
sites of the wrist, upper arm, rib, hip or spine – with the 
reason for this being unknown [66]. In subgroup analysis, 
this association between bariatric surgery and increased 
fracture risk was found to be stronger with RYGB surgery 
than with sleeve gastrectomy or other surgery types [66]. 
In keeping with these findings, a population-based, his-
torical cohort study of the medical records of 258 patients 
that had bariatric surgery between 1985 and 2004 found 
that these patients, over 94% of which had RYGB, carried 
a higher fracture risk than that of the general population, 
with an odds ratio of 2.3 (1.8–2.8) [67]. This risk was higher 
for fractures not only at the traditional osteoporotic sites 
of the hip, wrist, spine and upper arm, but also at non-
osteoporotic sites such as the foot, leg or hand [67]. These 
two studies [66, 67] are in contrast to a population-based, 
retrospective cohort study on 2079 surgical patients, 
which found no evidence of association between bariatric 
surgery and fracture [68]. However, this could be due to 
the fact that in this latter cohort study, over 60% of the 
surgical population had undergone gastric banding rather 
than RYGB [68].
In keeping with loss of BMD, elevated serum con-
centrations of bone formation and resorption markers, 
namely osteocalcin [69, 70] and NTX [70], respectively, 
have been reported after RYGB surgery relative to pre-
surgery values. Increases in bone turnover markers have 
also been observed in response to gastric banding and 
sleeve gastrectomy [10]. A meta-analysis of 10 studies 
involving a total of 344 patients confirmed that whilst 
total body, femoral neck, lumbar spine and pelvic BMD 
were significantly decreased post-surgery, serum or 
urinary concentrations of NTX were significantly elevated 
[54]. This meta-analysis noted interesting differences in 
serum concentrations of nutrients that are important 
for the maintenance of bone mass, namely calcium and 
vitamin D. That is, serum calcium concentrations were 
significantly reduced post-bariatric surgery, although 
no difference could be found in serum concentrations 
of vitamin D [54]. A prospective study of 73 patients who 
were followed for 18 months post-bariatric surgery found 
that urinary NTX concentrations increased significantly 
by 3  months and remained significantly higher for the 
duration of the study period, whilst serum calcium con-
centrations remained stable [53]. This lack of effect of 
bariatric surgery on serum calcium levels could be due 
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to aggressive calcium supplementation pre- and post-
surgery, however serum vitamin D levels increased by 
3 months post-surgery and then decreased to insufficient 
levels of < 30 ng/mL by 18 months post-surgery, despite 
vitamin D supplementation [53]. A similarly less than 
desirable level of serum vitamin D was also reported in 
a 12-month prospective longitudinal study on 23 men 
and women who underwent RYGB surgery [60]. This 
study reported that despite vitamin D intake increasing 
from an average of 658 IU/day at baseline to 1698 IU/
day at 12 months, 87% of patients had insufficient serum 
levels of vitamin D at 12 months (≤ 30 ng/mL) [60]. It has 
been suggested that current post-surgery supplementa-
tion recommendations of 1200–2000  mg calcium daily 
and 1000 IU vitamin D daily [71] may be insufficient for 
bariatric patients post-operatively [54]. In summary, bone 
turnover appears to increase after bariatric surgery, and 
there is a need for vigilance for nutritional deficiencies 
both pre- and post-surgery [60].
A recent report [72] has highlighted the possibility 
that the substantial reductions in BMD seen after RYGB 
may be due to artifacts of DXA scanning in the context 
of large weight losses in people with morbid obesity. 
For instance, DXA scans revealed significant reduc-
tions in hip BMD at 12 months after RYGB, in compari-
son to pre-surgical values and non-surgical controls, 
but CT scans detected no such decrease in hip BMD [72]. 
These findings cast doubt over the existence or magni-
tude of BMD reductions in response to bariatric surgery, 
and potentially also in response to other obesity treat-
ments. However, a more recent study with CT detected 
adverse effects of RYGB on BMD, microarchitecture and 
estimated strength at 12  months after surgery, at least 
in the tibia, which is a weight-bearing bone (only tibia 
and radius were assessed by CT, not hip or spine) [73]. 
Moreover, an adverse effect of RYGB on bone can be 
deduced by observations of concurrent increases in cir-
culating concentrations of bone turnover markers such 
as P1NP and CTX in the aforementioned CT study [72] 
and in other studies [54, 69, 70], and by the evidence 
of increased fracture risk following bariatric surgery 
that has been reported in some [66, 67] but not all [68] 
studies.
Despite the link between bariatric surgery and poten-
tially adverse changes in bone, many factors need to be 
taken into account, including the risk of obesity itself, 
when deciding on surgery. As the number of bariatric sur-
gical operations increase, notably in younger patients, it 
is important that these factors are fully understood, par-
ticularly the potential effect of bariatric surgery on long-
term fracture risk [11].
Effect of weight loss pharmaceuticals on 
bone
International [74, 75] and national [76] organizations rec-
ommend that pharmacotherapy be considered for the 
treatment of obesity, as an adjunct to lifestyle changes, 
for people with a BMI > 30 kg/m2, or BMI ≥ 27 kg/m2 with 
at least one comorbid medical condition such as hyper-
tension, dyslipidemia, type 2 diabetes mellitus (T2DM) or 
obstructive sleep apnea. In terms of available pharmaco-
therapy, orlistat, liraglutide and naltrexone + bupropion 
are currently approved as weight loss medications by the 
European Medicines Agency in Europe, while orlistat, 
liraglutide, naltrexone + bupropion, phentermine + topira-
mate and lorcaserin have current approval by the Food 
and Drug Administration in the USA [77]. In Australia, the 
Therapeutic Goods Administration has approved orlistat 
and more recently liraglutide for the long-term treatment 
of obesity, while phentermine is available as a short-term 
obesity treatment of up to 3 months. No literature was 
found on the effects of naltrexone + bupropion, phenter-
mine, phentermine + topiramate or lorcaserin on bone. 
Therefore, this review will focus on the pharmacological 
agents orlistat and liraglutide [a glucagon-like peptide-1 
(GLP-1) receptor agonist], as well as another GLP-1 receptor 
agonist, exenatide, and their association with bone health.
Orlistat
Orlistat is a potent and selective inhibitor of gastrointes-
tinal lipase, reducing intestinal fat absorption by up to 
30%, resulting in a loss of body weight over and above 
that of placebo when combined with a well balanced, 
mildly energy-restricted diet [78]. It is approved for long-
term therapy and is available by prescription and over the 
counter in 120 mg and 60 mg strengths, respectively.
A single clinical trial suggests that orlistat is not 
associated with any loss of BMD or bone mineral content 
(BMC) over and above the effect of placebo and associated 
weight loss [79]. This 12-month, prospective, randomized, 
placebo-controlled trial of orlistat treatment (120 mg, 3 
times a day) in 30 obese participants with a mean age of 
41 ± 11 years, showed that mean forearm BMD decreased 
significantly by 0.01 g/cm2 from pre-treatment values 
to 12  months in the orlistat group, with no difference in 
treatment effect between the orlistat and placebo groups. 
The changes in lumbar spine and total body BMD from 
pre-treatment to 12 months were not significant in either 
group. Significant weight losses of 11.2 ± 7.5 kg (mean ± SD) 
and 8.1 ± 7.5 kg were measured in the orlistat and placebo 
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groups, respectively, albeit the difference between groups 
was not significant in this particular trial [79].
The above-mentioned results from DXA measure-
ments were supported by measurement of bone formation 
markers, including serum concentrations of osteocalcin, 
and bone resorption markers, including the fU-OHpr/creat 
ratio, as well as indicators of calcium metabolism and 
vitamin D status [79]. Although a number of these param-
eters changed significantly from baseline, there were no 
significant differences between the orlistat and placebo 
treatment groups, with the exception of the fU-OHpr/creat 
ratio. In the orlistat group, the mean fU-OHpr/creat ratio 
increased significantly, resulting in a significantly higher 
mean value at 12  months in the orlistat compared with 
the placebo group. This finding may indicate an increase 
in bone turnover in favor of resorption with orlistat treat-
ment, however the fU-OHpr/creat ratio is not one of the 
more recently recommended markers of bone resorp-
tion [40–42], so these results should be interpreted with 
caution.
Similar to the above findings, another randomized, 
placebo-controlled study conducted in 28 men with 
obesity, found that serum concentrations of markers 
of bone turnover did not differ between the orlistat and 
placebo groups following 21  days of orlistat treatment 
(120 mg, 3 times daily) [80]. Although these results do not 
indicate any detrimental effect on bone turnover, it is dif-
ficult to draw any conclusions regarding bone health with 
only 21 days of drug exposure.
Taken together, these findings suggest that orlistat 
does not have a negative impact on bone health, beyond 
that of placebo and what might be expected as a result of 
weight loss. However, given the limited data available, 
further research is needed before the effects of orlistat on 
bone metabolism can be conclusively reported.
GLP-1 receptor agonists
GLP-1 is an incretin hormone secreted by the gut in 
response to nutrients, especially glucose. It is involved in 
the maintenance of glycaemic control and also reduces 
gastric emptying and results in a decrease in appetite and 
food intake [81].
The GLP-1 receptor agonists, namely liraglutide and 
exenatide, were developed and approved for the treat-
ment of T2DM due to their glycaemic control properties. 
Liraglutide has also been approved for weight manage-
ment at a higher dose (3 mg/day) than that used to treat 
T2DM (1.8 mg/day). Exenatide has not been approved for 
the treatment of obesity, however, has shown weight loss 
properties in clinical trials [82, 83].
A recent meta-analysis reported that liraglutide 
treatment, at doses typically used to treat T2DM, is asso-
ciated with a significantly reduced risk of bone fracture 
at any site, while exenatide treatment is associated with 
an elevated risk [84]. This meta-analysis included 16 
randomized controlled trials with a total of 11,206 partic-
ipants (mean age ranging from 45.9 to 59.5 years). Partici-
pants with pre-existing osteoporosis were excluded. The 
overall risk of bone fracture was not influenced by GLP-1 
receptor agonists (liraglutide and exenatide combined), 
with an odds ratio of 1.05 (95% confidence interval 0.59–
1.87), when compared with other drugs or placebo. This 
is a similar finding to another meta- analysis published 
a year earlier, of seven randomized controlled trials spe-
cifically involving people with T2DM, which found that 
treatment with GLP-1 receptor agonists did not modify 
the risk of fractures [85]. However, when considered 
separately, the eight randomized controlled trials of 
liraglutide treatment were collectively associated with 
a significantly reduced risk of bone fracture compared 
with placebo or other active drugs [odds ratio 0.38 
(0.17–0.87)] [84]. It should be noted that in two of these 
eight trials, exenatide was the comparator. Although the 
trend remained even after these two trials were removed 
from the analysis, the difference in risk was no longer 
statistically significant (odds ratio 0.49 [0.19–1.22)]. In 
contrast to liraglutide, there was a significantly greater 
risk of bone fracture in the exenatide treatment group 
compared to the comparator group, with an odds ratio 
of 2.09 (1.03–4.21) [84]. Excluding the two studies with 
liraglutide as the comparator still resulted in an elevated 
odds ratio of 1.71 (0.80–3.67).
A number of limitations are worth noting in this 
meta-analysis [84], including the overall lack of avail-
able data on the impact of GLP-1 receptor agonists on 
bone turnover. In addition, the studies included were not 
designed to assess the risk of fracture and only 43 frac-
tures were reported in total, mostly as serious adverse 
events. As such, there may have been a number of unre-
ported fracture incidents. Moreover, the length of most 
trials were not long enough to adequately assess the risk 
of fracture. The studies included were between 12 and 
104 weeks in duration, with 11 out of 16 trials being 26 
weeks in duration or less. Also, concomitant medica-
tions such as statins, corticosteroids and estrogens were 
not routinely reported in all studies involved in the meta-
analysis, and may have influenced bone strength and the 
resultant risk of fracture.
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Despite these limitations, another study provides 
some degree of support for the positive findings of the 
effect of liraglutide on fracture risk [86]. In this study, 
37  non-diabetic, obese women, aged 46 ± 2 years, com-
pleted an 8-week meal replacement weight loss program 
and were then randomized into a liraglutide group 
(1.2  mg/day, which is less than half the dose of liraglu-
tide used for weight management, n = 18) or a control (not 
placebo) group (n = 19). Both groups followed a weight 
maintenance program for the duration of the 52-week phar-
maceutical treatment phase. There were no differences in 
weight loss or weight maintenance between groups. Pelvic 
BMD decreased significantly from baseline (after weight 
loss) to the end of the 52-week weight maintenance period 
in both the liraglutide group (–0.03 ± 0.01 g/cm2, p < 0.01) 
and the control group (–0.02 ± 0.008 g/cm2, p < 0.05), with 
no significant difference in treatment effect between the 
two groups. There was no significant change in total body 
or arm-leg BMD in either group. While the gold standard 
for measuring bone mass is via localized scans of specific 
bones such as the hip or spine, rather than the whole body 
scans used for this study, and while bone mass is most 
commonly reported in density units, the authors of this 
study noted that although the liraglutide group showed 
small, non-significant decreases in pelvic, total body and 
arm-leg BMC as a result of the 52-week weight mainte-
nance phase, the control group showed a significant loss 
of BMC at all three locations.
Despite limitations in the methods used to determine 
the above-mentioned changes in bone mass, changes 
in bone turnover markers observed in this study also 
supported a favorable effect of liraglutide [86]. Indeed, 
there were significant, 11%–16% increases in plasma 
concentrations of the bone formation markers P1NP and 
osteocalcin during liraglutide treatment, in contrast to 
non-significant changes in the control group. There was 
a significant decrease in plasma vitamin D concentra-
tions in the control group, in contrast to a non-significant 
decrease in the liraglutide group. There was no significant 
change in the plasma concentrations of the bone resorp-
tion marker CTX in either group [86]. These findings for 
P1NP/osteocalcin and CTX, markers of bone formation 
and resorption, respectively, suggest that the beneficial 
effect of liraglutide may be to promote bone formation 
rather than the prevention of bone resorption.
In contrast to these seemingly positive effects of GLP-1 
receptor agonists on bone metabolism, no positive effects 
were observed in a population-based medical record-
linked cohort study. This study included a total of 216,816 
individuals with T2DM, 8354 of which were current, recent 
or past users of a GLP-1 receptor agonist, with a median use 
of 1.7 years and median follow-up of 5.1 years [87]. Median 
follow-up of patients with no exposure to GLP-1 receptor 
agonists was 3.6 years. Overall, this class of drug showed 
no effect on osteoporotic bone fracture risk. In addition, 
stratification by GLP-1 receptor agonist type used (liraglu-
tide or exenatide), revealed no decrease or increase in the 
risk of fracture [87].
Although there is a lack of data on the impact of 
GLP-1 receptor agonists on bone metabolism, the current 
literature concurs that this and other pharmacotherapy 
for weight loss do not negatively impact bone integrity 
beyond the effect of placebo and associated weight loss, 
and that there is no associated increased risk of fracture. 
Further research is needed however to confirm these find-
ings, and the extent of any potential beneficial effects that 
liraglutide may have on bone.
Effects of dietary restriction on bone
As seen above, treatments for obesity, particularly bari-
atric surgery, have been associated with bone loss. Given 
that dietary restriction is the first treatment choice for 
obesity, and is also an essential component of surgical 
and pharmacological obesity treatments, studies investi-
gating whether diet-induced weight loss is also associated 
with bone loss have emerged.
Similarly to bariatric surgery studies, a recent meta-
analysis found a significant reduction in hip BMD after 
diet-induced weight loss interventions of 6–24 (but not 
3) months in duration [34]. These reductions in total hip 
BMD were between 0.010 and 0.015 g/cm2, which corre-
sponds to an approximate change of 1%–1.5% from pre-
treatment values [34]. While statistically significant, these 
diet-induced reductions in hip BMD are considerably less 
than those associated with bariatric surgery (RYGB spe-
cifically), which showed a decline of 8%–11% from pre-
surgical values in the first 12  months post surgery [10, 
50, 56, 59, 60]. In accordance with the high variability of 
results, the lumbar spine showed no significant change in 
BMD with diet-induced weight loss [34]. Total body BMD 
decreased with diet-induced weight loss in both pre- and 
post-menopausal women, but was only significant in 
post-menopausal groups [34]. Serum concentrations of 
osteocalcin, but not P1NP, both of which are markers of 
bone formation, increased significantly from baseline 
during 3-month weight loss interventions, however no 
effect was found in interventions with a longer duration 
[34]. Similarly, serum concentrations of the bone resorp-
tion markers, CTX and NTX, increased significantly 
after dietary weight loss interventions of 2 or 3  months 
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in duration [34]. Given that the serum concentrations of 
these bone turnover markers increased transiently prior 
to the decrease in total hip BMD observed after interven-
tions of 6 months or longer, these findings indicate that 
dietary restriction-induced weight loss results in a real, 
albeit small and statistically significant, decline in total 
hip BMD [34].
In addition to dietary restriction for the purposes of 
weight loss, another dietary intervention that has been 
linked with bone loss is long-term energy restriction, often 
referred to as calorie restriction, as a means of potentially 
increasing longevity and slowing biological aging [88]. 
A randomized controlled trial in 218 non-obese younger 
adults (aged 20–50 years), randomized to either 24 months 
of energy restriction or ad libitum intake, found that total 
hip BMD declined significantly compared to pre-treatment 
values at 24 months in the restricted compared to the ad 
libitum group (–0.017 ± 0.002 vs. 0.001 ± 0.003 g/cm2) [89]. 
This reduction in hip BMD in the energy-restricted group 
correlated with weight loss [89]. Serum  concentrations 
of the bone formation marker PINP did not change at 
6 months, while that of BAP significantly decreased relative 
to pre-treatment at 12  months and remained suppressed 
at 24 months in the energy-restricted as compared to the 
ad libitum group [89]. This lack of change or reduction 
in bone formation markers was coupled with significant 
increases over pre-treatment values in serum concentra-
tions of the bone resorption markers CTX and TRAP5B 
at 6 and 12 months in the energy-restricted compared to 
the ad libitum group [89], indicating an uncoupling of 
the bone turnover process which likely contributed to 
the loss of BMD in this cohort of younger adults [89]. In 
contrast to this finding of hip BMD loss with long-term 
energy restriction in younger adults, diet-induced weight 
loss in younger adults – unlike in older adults – has not 
been associated with similar decreases in BMD despite 
weight losses of 7%–10% from baseline [90–92]. Higher 
muscle mass and the hormonal profile of younger adults 
are thought to protect against the negative skeletal effects 
of diet-induced weight loss [93]. The aforementioned 
negative effects of long-term energy restriction versus 
ad libitum intake could thus be  attributed to the lower fat 
free mass of the non-obese younger adults studied in that 
trial, compared to the higher fat free mass of individuals 
with overweight or obesity [89]. However, the impact of 
this small but significant decrease in hip BMD with long-
term energy restriction in non-obese adults on fracture 
risk, as assessed using the World Health Organization 
fracture risk assessment tool, appears small [89].
It appears unlikely that a single dietary weight loss 
intervention would lead to an overall negative impact 
on bone as compared to the metabolic advantages that 
weight loss confers to a person with overweight or obesity. 
There is speculation that bone loss in response to diet-
induced weight loss is a normal adaptation to a lighter 
body [93], akin to the finding that significant reductions 
in fat free mass are also a normal adaptation to weight loss 
in adults with overweight or obesity [94]. Furthermore, it 
has been suggested that while BMD may decline due to 
diet-induced weight loss, bone quality – as assessed by 
high resolution magnetic resonance imaging of trabecu-
lar bone microarchitecture – does not [95]. However, very 
rarely in obesity is a single weight loss attempt the end 
point of dietary interventions in an effort to lose weight 
[12, 34]. Usually, multiple attempts at weight loss and 
periods of dietary restriction are followed by regain, over 
many years [12, 34]. Moreover, studies have shown that 
BMD lost from the hip or lumbar spine over 6 months of 
diet-induced weight loss was not recovered during weight 
regain when measured at the 12- and 18-month time points 
[96, 97]. Due to these results suggesting that diet-induced 
bone loss is not recovered during weight regain, there is a 
risk that weight cycling – weight loss followed by regain, 
occurring 1 or more times – may place people who undergo 
repeated attempts to lose weight via dietary restriction at 
an increased risk of adverse effects on bone, particularly 
those at higher risk of bone loss such as inactive and older 
women [12, 34]. This finding has been suggested in a large 
population-based study of 20,745 females and males over 
15  years of age [98]. Females who reported their largest 
weight loss as being 11 kg or more, or who recalled having 
dieted over 11 times over their life, had an adjusted hazard 
ratio of 1.48 (95% confidence interval: 1.13–1.94) and 1.73 
(1.11–2.68) for osteoporotic fractures, respectively [98].
While diet-induced weight loss is associated with 
small but significant losses of BMD, lifestyle factors – 
notably exercise and nutrition – are likely to attenuate any 
potential long-term deleterious effects. These factors will 
be discussed in greater detail in the next section.
Given that obesity is a major health concern that 
confers risk in many areas of health, and given the meta-
bolic advantages of weight loss, it appears that a single 
weight loss intervention via dietary restriction with a 
view to weight maintenance holds little risk to bone 
health, as compared to the known adverse health conse-
quences of remaining obese [34]. Thus, clinicians should 
continue to recommend dietary restriction for weight 
loss, with a view to long term weight maintenance, for 
clients with overweight or obesity, with the addition of 
weight-bearing exercise and adequate dietary intake of 
nutrients, notably calcium and protein, for the reasons 
outlined below.
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Possible mechanisms of bone loss 
induced by obesity treatments
A number of mechanisms have been proposed for the loss 
of BMD during obesity treatments, and some of these – to 
be discussed here – represent potential points of lifestyle 
intervention to prevent adverse effects on bone.
A major contributing factor common to all modalities 
of obesity treatment seems to be the reduction in mechani-
cal loading on bone as a consequence of weight loss [12], 
which stimulates the secretion by osteocytes of sclerostin, 
a protein that inhibits bone formation [99]. This mecha-
nism could explain the observation that bariatric surgeries 
induce greater bone losses than other obesity treatments, 
as summarized in Table 1, because they also induce greater 
weight loss. In keeping with the notion of mechanical 
unloading contributing to bone loss with obesity treat-
ments, loss of hip BMD was found to be strongly and signifi-
cantly correlated with loss of body weight in 23 participants 
at 12 months post-RYGB [60], as well as in 218 non-obese 
participants after 24  months of dietary restriction [89]. If 
mechanical unloading contributes to bone loss, possibly 
and at least partially via changes in sclerostin secretion, 
then weight-bearing exercises (which includes resistance 
training and high impact weight bearing exercises such 
as running, jogging, skipping and dancing) might be 
expected to overcome this effect. Meta-analyses conclu-
sively report that weight bearing exercises – notably resist-
ance training combined with high impact weight bearing 
exercise – significantly preserve BMD compared to other 
forms of exercise, including jogging mixed with walking 
or stair climbing or agility exercises, in pre- or post-men-
opausal women [100–102]. In one of these meta-analyses, 
resistance training combined with high-impact weight 
bearing exercises was found to be better at enhancing BMD 
in postmenopausal women than resistance training alone 
[101]. Moreover exercise, particularly weight-bearing exer-
cise, has been shown to reduce BMD losses during dietary 
restriction [93, 103]. In addition, exercise-induced weight 
loss without dietary restriction does not appear to induce 
the significant decreases in BMD that have been observed 
with weight loss induced by dietary restriction alone [104]. 
Interestingly, sclerostin levels have been found to increase 
in people with overweight or obesity who are prescribed 
dietary restriction without specific addition, or supervi-
sion, of physical activity [99, 105, 106]. Moreover, a weight 
loss diet, when combined with both aerobic and resistance 
training, prevented the increase in circulating sclerostin 
levels otherwise associated with dietary restriction, con-
solidating a possible role of sclerostin in mediating effects 
of mechanical unloading and weight-bearing exercises on 
bone [106].
Another factor that could conceivably contribute to 
BMD losses with obesity treatments – and which, like 
weight bearing, holds potential for intervention via life-
style changes – is reduced intake and/or absorption 
of nutrients that help to maintain bone mass, notably 
protein, calcium and possibly also vitamin D. This is par-
ticularly true of bariatric surgery, where not only is dietary 
intake reduced, but malabsorption in the gastrointestinal 
tract can further exacerbate nutritional deficiencies [107]. 
In keeping with a role of nutrient depletion in promoting 
bone loss, BMD loss with obesity treatments can be sig-
nificantly attenuated or prevented by ensuring adequate 
dietary (or supplemental) intake of calcium, protein and – 
in the bariatric surgery population – potentially also 
vitamin D [12, 93]. A randomized controlled trial showed 
that in young adults, preserving normal dietary levels 
of calcium during moderate energy restriction, with or 
without exercise, helped to conserve hip and total body 
BMD during weight loss [91]. Similarly, in a randomized 
controlled trial in overweight pre-menopausal women, 
both adequate as well as high calcium intakes were shown 
to attenuate BMD loss during weight loss [90]. In addi-
tion, randomized controlled trials have found that higher 
protein diets (∼86 g/day or 24% of energy intake) confer 
protection against significant bone loss and may decrease 
bone turnover during diet-induced weight loss [12, 37, 93, 
108]. The benefits of vitamin D supplementation to pre-
serve hip BMD during dietary restriction-induced weight 
loss have recently been called into question, with the 
observation that it did not attenuate hip BMD loss in a ran-
domized placebo-controlled trial involving 218 post-men-
opausal women with vitamin D insufficiency [109]. This 
may be related to the fact that in addition to vitamin D 
supplementation, women in that trial also underwent an 
aerobic exercise program that was partly supervised by an 
exercise physiologist [109], which may have also reduced 
BMD loss [100–102]. Taken together, these findings imply 
that ensuring that calcium and protein intake are optimal, 
as well as that of vitamin D in people undergoing bariatric 
surgery, and including weight-bearing exercise, could be 
useful strategies to help mitigate any loss of BMD during 
obesity treatments.
There are many other mechanisms besides reduced 
weight bearing and nutritional status that are hypothe-
sized to contribute to bone loss during obesity treatments. 
These include alterations in hypothalamic neuropep-
tide expression in response to energy deficit, notably an 
increase in that of neuropeptide Y [23], alterations in cir-
culating concentrations of gut-derived appetite-regulating 
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hormones, notably peptide YY and GLP-1 [10, 11], reduc-
tions in active levels of other hormones such as sex hor-
mones and insulin-like growth factor [110], and – in the 
bariatric population – changes in vitamin D and parathy-
roid hormone status (not strongly supported by the lit-
erature) or adipokines [33, 111]. These potential pathways 
are not discussed in detail here, because they are not as 
readily amenable to intervention via lifestyle factors as are 
mechanical unloading and nutritional deficiencies, and 
the reader is referred to the reviews cited in this paragraph 
for further information.
Expert opinion
In summary, all obesity treatments under review in 
this work – bariatric surgery, weight loss pharmaceuti-
cals and dietary restriction alone – have been shown to 
result in statistically significant decreases in BMD of the 
hip, as well as statistically significant increases in bone 
turnover, as indicated by perturbations in circulating or 
urinary concentrations of bone turnover markers. The 
loss of hip BMD relative to pre-treatment values is great-
est for bariatric surgery – notably RYGB for which most 
research in this field has been conducted (8%–11% of pre-
surgery values) – and is least for dietary restriction alone 
(1%–1.5% of pre-intervention values), with weight loss 
pharmaceuticals (orlistat or the GLP-1 receptor agonist 
liraglutide) inducing no greater loss in hip BMD than 
that induced by the control condition of the same dietary 
restriction with or without placebo. This finding of similar 
hip BMD losses in both groups despite generally greater 
weight losses in the groups taking active agents suggests 
a potential protective effect of these weight loss pharma-
ceuticals on bone. Indeed, a limited amount of research 
has suggested that the GLP-1 receptor agonist liraglutide 
may actually increase BMC (but not BMD) and decrease 
fracture risk relative to control, but more research is war-
ranted to assess this.
An interesting observation to arise from considering 
these three different obesity treatments together is that 
unlike their clear effects to reduce hip BMD, none of them 
had any clear unidirectional effect on spine BMD. A possi-
ble interpretation for this is that obesity treatments affect 
the weight-bearing site of the hip more readily than they 
affect the spine, but an alternate explanation is that the 
spine is more prone to measurement error via DXA than 
the hip. DXA scans of the spine, in particular the lumbar 
region (L1–L5), often pick up calcification from other 
sources besides healthy vertebrae, and this increases 
apparent BMD readings [112, 113]. Such calcification can 
originate from atherosclerotic lesions within the aorta, 
or from osteophytes (protrusions of bone tissue that form 
in response to joint damage from conditions such as in 
arthritis), masking underlying changes in bone mass due 
to age, disease, or other factors [112–114]. As such, ongoing 
research in this field could benefit from a preferential 
focus on hip over spine DXA. This could help in situations 
where the time available for DXA scans is limiting, where 
radiation exposure needs to be minimized (e.g. when 
assessing minors or when multiple DXA scans are being 
undertaken over a relatively short time frame), or when 
participants have features on their spine that make it diffi-
cult to assess changes in BMD due to various interventions 
(e.g. atherosclerosis or arthritis).
While the meta-analyses synthesized here show a 
clear effect of obesity treatments to reduce hip BMD, it 
is not known whether this is a maladaptive change, or 
whether it simply represents normalization of BMD rela-
tive to reduced body mass, akin to the finding that a certain 
loss of percent fat-free mass is to be expected in response 
to reduced BMI [94]. It is also not known whether the 
observed reductions in hip BMD persist or worsen years 
after completion of the intervention, as suggested in some 
[63] but not all [55] of a limited number of studies that 
assessed bone at > 12 months after bariatric surgery. This 
question is currently under investigation in the context 
of dietary restriction in two long-term (36-month) clinical 
trials from our team [115, 116]. Most importantly, it is not 
known whether or not this reduced BMD contributes to a 
greater fracture risk, as has been suggested by some [66, 
67] but not all [68] studies post-bariatric surgery, particu-
larly RYGB, and how any potential increase in fracture risk 
compares to the risk of not treating obesity. While reduced 
BMD is certainly an indicator of increased fracture risk, it 
is not a perfect predictor, and a reduction in BMD per se is 
not necessarily a path to disease.
In light of these outstanding questions, and in light 
of the known benefits of losing 3%–15% or more of body 
weight on multiple aspects of health [117], any concerns 
about potential effects of obesity treatments on bone 
health should not deter against treating overweight or 
obesity. However, and also in light of these outstanding 
questions, it is prudent to implement strategies that are 
likely to mitigate bone loss during obesity treatments, 
particularly in those at higher risk of bone loss such as 
older adults. These include emphasizing the importance 
of consuming nutrient-rich foods in favor of nutrient-poor 
foods with a high energy density, with possible supple-
mentation, thereby helping to ensure adequate intake of 
nutrients – notably protein, calcium and possibly also 
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vitamin D – as well as emphasis of the importance of exer-
cise, all of which have been shown to help maintain BMD 
during weight loss.
Outlook
In 5–10 years from the time of writing this review, we spec-
ulate that this field will have evolved (or should evolve) by 
combining data sets from multiple clinical trials in order 
to determine whether the presently observed reductions 
in hip BMD in response to obesity treatments represent 
benign normalization of bone mass to the reduced body 
weight, or the onset of potentially pathological processes. 
In addition, we propose the importance of long-term pro-
spective studies – 36  months and longer – to determine 
whether reductions in hip BMD with obesity treatments 
are reversible, with or without weight regain, and (using 
data linkage with medical records, for example) whether 
fracture risk is elevated by obesity treatments relative to 
untreated overweight or obesity. We also propose that sys-
tematic reviews and meta-analyses be conducted on the 
many trials that have investigated interventions aimed at 
reducing bone loss during obesity treatments, so that the 
best evidence-based interventions can be implemented 
now, to protect against eventual adverse effects of obesity 
treatments on bone, particularly in those at higher risk of 
bone loss.
Highlights
 – Obesity appears to compromise bone mass and may 
increase fracture risk.
 – Recent meta-analyses show that obesity treatments 
(surgical, pharmacological and dietary) reduce BMD 
of the hip, with no clear effect on the spine, perhaps 
due to greater measurement artifact in the spine.
 – Ongoing research in this area could be stream-
lined by focusing on hip in favor of spine BMD 
measurements.
 – As hip BMD is a major determinant of osteoporotic 
fracture risk, reduced hip BMD could conceivably 
increase the risk of fractures with obesity treatments.
 – RYGB has been suggested to increase osteoporotic 
fracture risk.
 – It is unknown if a single obesity intervention involv-
ing dietary restriction, with or without weight loss 
pharmaceuticals, increases the risk of fracture, but 
any such increase is likely to be small relative to the 
cardio metabolic and other health benefits of loss of 
excess weight.
 – There is little information as to whether BMD losses 
during obesity treatments are recovered post- 
treatment, but focusing on weight maintenance after 
obesity treatment would be prudent for bone health.
 – Lifestyle interventions that have been suggested to 
reduce BMD loss with obesity treatments are increased 
dietary intake of protein, calcium and potentially also 
vitamin D, as well as increasing physical activity, 
notably weight-bearing exercise.
 – Meta-analyses would help to determine the best evi-
dence-based interventions against potential adverse 
effects on bone health with obesity treatments.
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